Date added: Tuesday 2nd August 2016
Latest updated: Wednesday 8th February 2017
Elstree, 1 August, 2016 - Bio Products Laboratory Ltd. ("BPL"), a leading plasma biotherapeutics company, today announces that a group controlled by Creat Group Corporation ("Creat"), has finalized the acquisition of BPL.
BPL, headquartered in Elstree, Hertfordshire, provides lifesaving therapeutics for conditions related to immune deficiencies, bleeding disorders, and critical care. BPL's plasma division, the largest supplier of US plasma to third parties, provides specialty and source plasma to manufacturers that also produce lifesaving therapies.
Creat, a leading Chinese investment group, will invest £100 million in BPL to expand production capacity of lifesaving therapies, develop new products and access new markets. BPL's existing management team is staying with the company, which will remain headquartered in the UK. Creat will support management's ambition to transform BPL into a global life-sciences champion, serving more customers and patients in a greater number of markets around the world. Creat is a long-term strategic investor with a track record of growing businesses and a deep knowledge of the plasma sector.
John Perkins, CEO of BPL, said:
"BPL has transformed into a growth company increasing supply and introducing new therapies to better serve patients. Creat is an ideal partner for BPL's next phase of growth. The entire BPL management team is excited to be working with Creat and is committed to the future of BPL."
Mr Wu Xu, CEO of Creat Group Corporation, said:
"We are very excited to partner with the BPL management team. We are committed to support BPL's growth ambition with additional investment and our deep knowledge and experience in sector"
About Bio Products Laboratory Ltd.
BPL (www.bpl.co.uk) is a leading manufacturer of plasma-derived protein therapies with global headquarters in Elstree, England, US headquarters for its Therapeutics operation in Durham, NC. The company exports to more than 45 countries worldwide. BPL has over 60 years of experience developing and manufacturing plasma-derived therapies since being established as part of the Lister Institute in 1950, and currently markets a wide range of products including coagulation factors, human immunoglobulins, and albumin. BPL is committed to continued investment in research and development to maintain its key position as a reliable supplier of high-quality products to patients and healthcare providers worldwide.
About Creat Group Corporation
Creat Group Corporation (www.creatgroup.com) is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, natural resources, and real estate. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai.
+44 (0) 20 8957 2315